海思科：子公司获得4个创新药临床试验批准通知书

Core Viewpoint - The company, Haikang (002653.SZ), announced that its subsidiary, Shanghai Haikang Shennuo Pharmaceutical Technology Co., Ltd., has received clinical trial approval for four innovative drugs from the National Medical Products Administration of China [2] Group 1: Drug Approvals - The approved drugs include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [2] - These drugs are intended for the treatment of inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [2] - All drugs are classified as Class 1 chemical drugs and possess independent intellectual property rights [2] Group 2: R&D Considerations - The company has highlighted that the research and development of innovative drugs involves long cycles, multiple stages, and high risks, indicating the uncertainties involved [2]